Lista de obras -

Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIVmac251 Acquisition.

artículo científico publicado en 2014

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

artículo científico publicado en 2016

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

artículo científico publicado en 2011

Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved

artículo científico publicado en 2014

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

artículo científico publicado en 2017

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency

artículo científico publicado en 2020

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations

artículo científico publicado en 2018

Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost

artículo científico publicado en 2015

Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC"

scientific article published on 15 October 2019

Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1

artículo científico publicado en 2011

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

artículo científico publicado en 2010

Erratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

artículo científico publicado en 2016

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions

scientific article published on 30 January 2020

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

artículo científico publicado en 2020

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci

artículo científico publicado en 2017

Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates

artículo científico publicado en 2015

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa

scientific article published on 01 September 2019

Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates

artículo científico publicado en 2018

Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies

artículo científico publicado en 2011

Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

artículo científico publicado en 2017

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

artículo científico publicado en 2016

Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost

article

Proceedings of the Frontiers of Retrovirology Conference 2016.

artículo científico publicado en 2016

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

artículo científico publicado en 2017

Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC

article

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

artículo científico publicado en 2020

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial

artículo científico publicado en 2016

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

artículo científico publicado en 2011

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

artículo científico publicado en 2018

Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates

artículo científico publicado en 2015

Lista de obras de

Adjuvant Dependent Mucosal V2 Responses and RAS Activation in Vaccine Induced Protection from SIVmac251 Acquisition.

Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors

Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.

Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency

Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations

Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost

Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC"

Crystal Structure of Human Antibody 2909 Reveals Conserved Features of Quaternary Structure-Specific Antibodies That Potently Neutralize HIV-1

Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1

Erratum: Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition

HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions

HIV-1 Vaccine Sequences Impact V1V2 Antibody Responses: A Comparison of Two Poxvirus Prime gp120 Boost Vaccine Regimens

HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci

Head-to-Head Comparison of Poxvirus NYVAC and ALVAC Vectors Expressing Identical HIV-1 Clade C Immunogens in Prime-Boost Combination with Env Protein in Nonhuman Primates

Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa

Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates

Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies

Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge

Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens

Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost

Proceedings of the Frontiers of Retrovirology Conference 2016.

Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial

Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC

Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines

Selection of HIV vaccine candidates for concurrent testing in an efficacy trial

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.

Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates